Nunzia Pharmaceutical Company (NUNZ) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerNunzia Pharmaceutical Company (NUNZ) trades at $0.0001. Nunzia Pharmaceutical Company focuses on manufacturing and distributing its nutraceutical product, Nunzia, targeting disorders like autism and ADHD. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for NUNZ: NUNZ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Nunzia Pharmaceutical Company (NUNZ) Healthcare & Pipeline Overview
Nunzia Pharmaceutical Company, formerly Arizona Gold and Onyx Mining, manufactures and distributes Nunzia, a nutraceutical targeting autism, ADHD, and PTSD. Operating in the specialty and generic drug sector, the company utilizes wholesalers and its website for distribution, facing competition in a market with established pharmaceutical players.
What Is the Investment Thesis for NUNZ?
Nunzia Pharmaceutical Company presents a high-risk, high-reward investment profile. The company's focus on a single nutraceutical product, Nunzia, creates both opportunity and vulnerability. Potential catalysts include positive clinical data supporting Nunzia's efficacy in treating target disorders, which could drive increased demand and revenue growth. However, the company's small market capitalization and limited financial resources pose significant risks. Successful expansion hinges on effective marketing, strategic partnerships, and navigating the regulatory landscape for nutraceuticals. Investors should closely monitor the company's cash flow, sales growth, and ability to secure additional funding to sustain operations.
Based on FMP financials and quantitative analysis
NUNZ Key Highlights
Nunzia Pharmaceutical Company's sole product is Nunzia, a nutraceutical targeting autism, fragile X, ADHD, and PTSD.
- The company distributes its product through wholesalers and its website, nunziapharma.com.
- Nunzia Pharmaceutical Company was formerly known as Arizona Gold and Onyx Mining Company, changing its name in 2018.
- The company's market capitalization is $0.00B as of 2026-03-18.
- The company's beta is -3.28, indicating high volatility relative to the market.
Who Are NUNZ's Competitors?
NUNZ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $6.31 | -2.92% | $25.5M | — |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | 39 5-pillar |
| PETS PetMed Express, Inc. | $1.36 | -0.73% | $29.1M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NUNZ's Key Strengths?
Proprietary nutraceutical product (Nunzia).
- Direct-to-consumer sales channel via website.
- Focus on specific disorders (autism, ADHD, PTSD).
- Established manufacturing and distribution rights for Nunzia.
What Are NUNZ's Weaknesses?
Limited product portfolio (single product dependency).
- Small market capitalization.
- Limited financial resources.
- Dependence on wholesalers for distribution.
What Are the Key Risks for NUNZ?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from larger pharmaceutical companies with greater resources and established market presence.
- Regulatory scrutiny regarding the marketing and labeling of Nunzia as a nutraceutical.
- Adverse events or safety concerns associated with Nunzia, leading to product recalls or lawsuits.
- Limited financial resources and dependence on external funding to sustain operations.
- The company's OTC listing presents liquidity and transparency challenges.
What Are NUNZ's Competitive Advantages?
- Proprietary Formulation: Nunzia Pharmaceutical Company owns the rights to manufacture, market, and distribute Nunzia.
- Brand Recognition: Brand recognition, if established, within the niche market of nutraceuticals for specific disorders.
- Direct-to-Consumer Channel: Direct sales through the company's website, nunziapharma.com.
What Does NUNZ Do?
Nunzia Pharmaceutical Company, originally incorporated in 1986 as Arizona Gold and Onyx Mining Company, underwent a significant transformation in February 2018 when it rebranded to focus on the pharmaceutical and nutraceutical industry. Headquartered in Long Beach, California, Nunzia specializes in the manufacturing, marketing, and distribution of its proprietary nutraceutical product, Nunzia. This product is formulated to address symptoms associated with various disorders, including autism, fragile X syndrome, ADHD, and PTSD. Nunzia Pharmaceutical Company primarily distributes its product through two channels: wholesalers and its direct-to-consumer online platform, nunziapharma.com. This dual approach aims to maximize market reach and cater to different customer preferences. The company's transition from mining to pharmaceuticals reflects a strategic shift towards a sector with potentially higher growth and societal impact. However, it also entails navigating the complex regulatory landscape and competitive dynamics of the pharmaceutical industry. As a relatively small player, Nunzia faces the challenge of establishing brand recognition and market share against larger, more established pharmaceutical companies.
What Products and Services Does NUNZ Offer?
- Manufactures Nunzia, a nutraceutical product.
- Markets Nunzia for the treatment of autism.
- Markets Nunzia for the treatment of fragile X syndrome.
- Markets Nunzia for the treatment of ADHD.
- Markets Nunzia for the treatment of PTSD.
- Distributes Nunzia through wholesalers.
- Distributes Nunzia through its website, nunziapharma.com.
How Does NUNZ Make Money?
- Develops and manufactures the nutraceutical Nunzia.
- Sells Nunzia through wholesale distribution channels.
- Generates revenue through direct-to-consumer sales via its website.
What Industry Does NUNZ Operate In?
Nunzia Pharmaceutical Company operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and evolving regulatory standards. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and growing demand for affordable medications. Companies like ARYX and ATTBF represent established players in this space. Nunzia's success depends on differentiating its nutraceutical product and effectively targeting specific patient populations. The nutraceutical market is experiencing growth, but faces scrutiny regarding product claims and efficacy.
Who Are NUNZ's Key Customers?
- Individuals with autism and their families.
- Individuals with fragile X syndrome and their families.
- Individuals with ADHD and their families.
- Individuals with PTSD.
- Wholesale distributors of nutraceutical products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Insider Activity
12 transactions · 8 purchases, 1 sales, 3 other transactions · 3 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Financial Health
Nunzia Pharmaceutical Company's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
Nunzia Pharmaceutical Company operates in the Healthcare sector. It is headquartered in Long Beach, US. The company is led by CEO Sara Gonzales. NUNZ has traded publicly since 2009.
NUNZ Latest News
No recent news available for NUNZ.
NUNZ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NUNZ.
Price Targets
Wall Street price target analysis for NUNZ.
NUNZ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NUNZ; grades run from A+ (80-100) to F (below 30).
Leadership: Sara Gonzales
CEO
Sara Gonzales serves as the CEO of Nunzia Pharmaceutical Company. Therefore, a comprehensive profile cannot be constructed at this time. Further research would be needed to ascertain her specific expertise and qualifications for leading the company.
Track Record: Due to the limited information available, it is not possible to assess Sara Gonzales's track record or highlight any specific achievements or strategic decisions made under her leadership. A thorough evaluation would require access to company performance data, strategic initiatives, and other relevant information.
NUNZ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nunzia Pharmaceutical Company may not meet the minimum financial or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to provide regular financial disclosures to the public. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, bankrupt entities, or companies with questionable business practices.
- OTC Tier: OTC Other
- Limited or no financial disclosures.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or misrepresentation.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Determine the company's capital structure and debt levels.
- Understand the risks associated with the OTC Other market.
- Consult with a qualified financial advisor.
- Company website and contact information.
- Independent verification of business operations.
- Any available press releases or news articles.
- Third-party reports or ratings (if available).
- Clear and transparent communication from management.
What Investors Ask About Nunzia Pharmaceutical Company (NUNZ) — Healthcare
What do analysts say about NUNZ stock?
Due to the lack of analyst coverage and financial data, it is not possible to provide a consensus view on the stock's valuation or growth prospects.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial data available for comprehensive analysis.
- OTC market carries inherent risks and uncertainties.